CSL Half Year Results Announcement & Investor Presentation

CSL delivered a net profit after tax of $1.62 billion2 for the first half of financial year 2023, steady at CC3. This included one-off costs associated with the acquisition of Vifor Pharma. Underlying profit (NPATA4 attributable to CSL shareholders) was $1.82 billion2, up 10% at CC3. Revenue was up 25% at CC3 • Strong growth in immunoglobulin and albumin sales • Record levels of plasma collections